Getting back to AZ's licensing of SNG-001, I think its brilliant...

Getting back to AZ's licensing of SNG-001, I think its brilliant news for Vapendavir. Biota now has a good comparator for Vap's licensing. $10M upfront and $225M milestones/development funding is very good. And Vap is more advanced and arguably better than SNG-001. I'm not a shareholder anymore so I wont check, but maybe somebody should check SNG-001's Phase 2a results and compare it to Vap's Phase 2a and 2b results.

The positive sign is Big Pharma are interested in Rhinovirus... which I had some doubts about....